Latest News accredited articles:

Stay connected by reading our dynamic News and Blogs page. Your gateway to the freshest updates, cutting-edge research, and profound insights from the constantly evolving realm of aesthetics.

Scottish clinics face closure risk amid licensing delays

Scotland’s campaigning trade union General and Municipal Workers’ Union (GMB) has warned that clinics seeking licensing from Healthcare Improvement Scotland (HIS) could face closure due to delays in the application process. In the report, GMB explains that, with an increase of applications due to forthcoming Scottish Government legislation, watchdog has

Read More »

Report highlights regulatory shortcomings amid innovation

MPs have branded the regulation of hair and beauty products in the UK “unacceptable” following the publication of a new report by the Parliamentary Science and Technology Committee. The report, launched on November 4, concluded that current regulation is confusing for prospective patients, practitioners and enforcement officers alike. It stated

Read More »

Welsh Conservatives urge caution over unregulated aesthetic

The Welsh Conservatives have called for greater public awareness of the risks associated with unregulated aesthetic treatments following the successful prosecution of an aesthetics provider by Healthcare Inspectorate Wales (HIW). The case followed an HIW investigation which found that an aesthetics provider in Bridgend, South Wales, had continued to offer

Read More »

CAP issues Enforcement Notice on sunbed ads

The Committee of Advertising Practice (CAP) has published an Enforcement Notice towards advertisements for sunbed use following health and medical claims. The CAP shares that several advertisers have made misleading health claims about sunbeds, including that they can ease eczema symptoms, improve brain function, fight inflammation and boost blood circulation.

Read More »

FDA warns of eye condition from GLP-1 use

The US Food and Drug Administration (FDA) has warned of a potential association between glucagon-like peptide-1 (GLP-1) receptor agonists and nonarteritic anterior ischemic optic neuropathy (NAION), requiring updated warning labels across the drug class. Affected medications include Novo Nordisk’s semaglutide, Eli Lilly’s tirzepatide and Sanofi’s insulin glargine/lixisenatide, shares the FDA.

Read More »

Market analysis indicates growth in energy-based device sector

New market analysis from global market intelligence firm The Business Research Company has highlighted several factors contributing to continued growth within the medical aesthetic energy-based device (EBD) sector. According to the report, the global EBD market is expected to grow from $5.89 billion in 2025 to $6.62 billion in 2026,

Read More »

ADAP develops Competency Framework

The Association of Dentists in Aesthetic Practice (ADAP) is publishing its first Education and Competency Framework for dentists working in medical aesthetics. Led by aesthetic practitioner Dr Rehanna Beckhurst, chair of ADAP’s Education and Training Committee, the framework will define what competent, safe practice looks like for General Dental Council

Read More »

JCCP names new education and training chair

The Joint Council for Cosmetic Practitioners (JCCP) has appointed aesthetic practitioner Dr Natasha Verma as chair for the Education and Training Committee. The JCCP shares that Dr Verma brings extensive experience across medical aesthetics, postgraduate education and educational governance. Her background includes developing accredited qualifications, overseeing quality assurance processes and supporting

Read More »

ES Aesthetic Solutions introduces collagen-peptide injectable

Aesthetic distributor ES Aesthetic Solutions debuted NouVys, a collagen-peptide injectable, to the UK market. According to the company, NouVys combines low molecular weight collagen peptides with Magnesium Ascorbyl Phosphate (MAP), a vitamin C derivative, designed to support collagen-related processes and help maintain the skin’s extracellular matrix. CE-marked and available to

Read More »

Relfydess receives approval for glabellar lines in China

Pharmaceutical company Galderma has announced that China’s National Medical Products Administration (NPA) has approved Relfydess (relabotulinumtoxinA) for the temporary improvement of moderate-to-severe glabellar lines in adults. The approval is supported by a local phase III study in China and data from the global RElabotulinumtoxin Aesthetic Development study (READY) clinical trial

Read More »